NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy

  1. Hurtado-Navarro, L.
  2. Cuenca-Zamora, E.J.
  3. Zamora, L.
  4. Bellosillo, B.
  5. Such, E.
  6. Soler-Espejo, E.
  7. Martínez-Banaclocha, H.
  8. Hernández-Rivas, J.M.
  9. Marco-Ayala, J.
  10. Martínez-Alarcón, L.
  11. Linares-Latorre, L.
  12. García-Ávila, S.
  13. Amat-Martínez, P.
  14. González, T.
  15. Arnan, M.
  16. Pomares-Marín, H.
  17. Carreño-Tarragona, G.
  18. Chen-Liang, T.H.
  19. Herranz, M.T.
  20. García-Palenciano, C.
  21. Morales, M.L.
  22. Jerez, A.
  23. Lozano, M.L.
  24. Teruel-Montoya, R.
  25. Pelegrín, P.
  26. Ferrer-Marín, F.
  27. Show all authors +
Journal:
Cell Reports Medicine

ISSN: 2666-3791

Year of publication: 2023

Volume: 4

Issue: 12

Type: Article

DOI: 10.1016/J.XCRM.2023.101329 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals